Figure 7. The PPARγ agonist, rosiglitazone, differentially regulates p17 biological activities.

THP-1 cells were pre-incubated 2 hours with rosiglitazone (1 µM) before administration of p17 recombinant protein (1 µg/ml for 18 hours). Total RNA was extracted and the relative mRNA expression of (A) proinflammatory cytokines and nuclear receptors, (B) co-stimulatory molecules and (C) proatherogenic genes was analyzed by Real-Time PCR. Values are expressed relative to not treated cells. Analysis was carried out in triplicate and the experiment was repeated twice. *P<0.05 versus not treated cells. **P<0.05 versus p17 stimulated cells.